Krystal Biotech, Inc. (NASDAQ:KRYS) Insider Suma Krishnan Sells 25,000 Shares of Stock

Krystal Biotech, Inc. (NASDAQ:KRYS) insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the sale, the insider now owns 1,500,882 shares of the company’s stock, valued at $296,814,424.32. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Krystal Biotech Price Performance

Shares of NASDAQ KRYS opened at $201.58 on Friday. The stock has a market cap of $5.79 billion, a PE ratio of 107.80 and a beta of 0.82. Krystal Biotech, Inc. has a 1 year low of $93.95 and a 1 year high of $219.34. The firm has a fifty day moving average price of $196.03 and a 200-day moving average price of $178.58.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings results on Monday, August 5th. The company reported $0.53 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.50 by $0.03. Krystal Biotech had a return on equity of 1.99% and a net margin of 63.73%. The business had revenue of $70.28 million during the quarter, compared to analyst estimates of $65.27 million. During the same quarter in the prior year, the business posted ($1.25) EPS. Krystal Biotech’s revenue for the quarter was up 70283900.0% compared to the same quarter last year. On average, research analysts expect that Krystal Biotech, Inc. will post 3.13 EPS for the current year.

Analyst Ratings Changes

A number of analysts recently commented on KRYS shares. HC Wainwright upped their price objective on Krystal Biotech from $200.00 to $221.00 and gave the company a “buy” rating in a research report on Wednesday, August 28th. Citigroup reiterated a “neutral” rating and issued a $204.00 price objective (up previously from $195.00) on shares of Krystal Biotech in a research note on Tuesday, August 6th. Cantor Fitzgerald restated an “overweight” rating on shares of Krystal Biotech in a research report on Thursday, August 29th. Evercore ISI increased their price target on shares of Krystal Biotech from $201.00 to $206.00 and gave the stock an “outperform” rating in a research report on Monday, August 12th. Finally, Chardan Capital boosted their price objective on shares of Krystal Biotech from $153.00 to $208.00 and gave the company a “buy” rating in a research report on Monday, August 5th. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $196.75.

Institutional Trading of Krystal Biotech

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Scout Investments Inc. purchased a new stake in Krystal Biotech during the 1st quarter valued at approximately $8,976,000. Fiera Capital Corp bought a new stake in Krystal Biotech in the 4th quarter valued at $1,973,000. Sei Investments Co. lifted its stake in Krystal Biotech by 128.3% in the 1st quarter. Sei Investments Co. now owns 33,752 shares of the company’s stock worth $6,005,000 after purchasing an additional 18,968 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Krystal Biotech by 1.5% during the 4th quarter. Vanguard Group Inc. now owns 2,435,774 shares of the company’s stock valued at $302,182,000 after purchasing an additional 35,632 shares during the last quarter. Finally, Janney Montgomery Scott LLC bought a new position in shares of Krystal Biotech during the 1st quarter valued at about $3,175,000. Institutional investors own 86.29% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).